Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network.
Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, Goizet C, Roume J, Rabilloud M, Saurin JC, Cottin V, Honnorat J, Coulet F, Giraud S, Calender A, Danesino C, Buscarini E, Plauchu H; French-Italian-Rendu-Osler Network. Lesca G, et al. Among authors: carette mf. Genet Med. 2007 Jan;9(1):14-22. doi: 10.1097/gim.0b013e31802d8373. Genet Med. 2007. PMID: 17224686 Free article.
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Dupuis-Girod S, et al. Among authors: carette mf. JAMA. 2012 Mar 7;307(9):948-55. doi: 10.1001/jama.2012.250. JAMA. 2012. PMID: 22396517 Clinical Trial.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G. Azzopardi N, et al. Among authors: carette mf. MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693. MAbs. 2015. PMID: 25751241 Free PMC article.
Imaging of hereditary hemorrhagic telangiectasia.
Carette MF, Nedelcu C, Tassart M, Grange JD, Wislez M, Khalil A. Carette MF, et al. Cardiovasc Intervent Radiol. 2009 Jul;32(4):745-57. doi: 10.1007/s00270-008-9344-2. Epub 2008 Oct 30. Cardiovasc Intervent Radiol. 2009. PMID: 18972161 Free PMC article. Review.
Non-invasive CT screening for pulmonary arteriovenous malformations in children with confirmed hereditary hemorrhagic telangiectasia: Results from two pediatric centers.
Soysal N, Eyries M, Verlhac S, Escabasse V, Remus N, Tamalet A, Rioux JY, Franchi-Abella S, Vasile M, Robert S, Delestrain C, Hau I, Ducou-Le Pointe H, Soubrier F, Carette MF, Epaud R. Soysal N, et al. Among authors: carette mf. Pediatr Pulmonol. 2017 May;52(5):642-649. doi: 10.1002/ppul.23649. Epub 2017 Feb 6. Pediatr Pulmonol. 2017. PMID: 28165669
[Hepatic involvement in hereditary hemorrhagic telangiectasia].
Bachmeyer C, Hervio P, Cabannes A, Carette MF, Khalil A. Bachmeyer C, et al. Among authors: carette mf. Presse Med. 2010 Jul-Aug;39(7-8):851-2. doi: 10.1016/j.lpm.2009.09.020. Epub 2009 Nov 22. Presse Med. 2010. PMID: 19932592 French. No abstract available.
Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.
Guilhem A, Fargeton AE, Simon AC, Duffau P, Harle JR, Lavigne C, Carette MF, Bletry O, Kaminsky P, Leguy V, Lerolle N, Roux D, Lambert M, Chinet T, Bonnet D, Dupuis-Girod S, Rivière S. Guilhem A, et al. Among authors: carette mf. PLoS One. 2017 Nov 30;12(11):e0188943. doi: 10.1371/journal.pone.0188943. eCollection 2017. PLoS One. 2017. PMID: 29190827 Free PMC article.
185 results